Known targets — ChEMBL curated mechanism
PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Azd-6482. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB known ✓ | P42338 | 19/20 | 1.00 |
| ▸ | PIK3CA known ✓ | P42336 | 14/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 5/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 3/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.77 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | DDX6 | P26196 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | CSK | P41240 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 1/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | AKT1 | P31749 | 1/20 | 0.84 |
| ▸ | AKT2 | P31751 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-6482 SCHEMBL1812377 | 1.00 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| Azd-6482 SCHEMBL29361545 | 1.00 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| Azd-6482 SCHEMBL825695 | 1.00 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL30780578 | 0.92 | PIK3CB (0.85) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL30780750 | 0.92 | PIK3CA (0.95) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL26137495 | 0.92 | PIK3CA (0.98) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL26137372 | 0.92 | PIK3CA (0.98) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL4348187 | 0.91 | PIK3CB (0.84) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL909768 | 0.91 | PIK3CB (0.84) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL4348197 | 0.91 | PIK3CB (0.84) | PIK3CBPIK3CAPIK3CDPIK3CGSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093972-A1 | ENANTIOMERICALLY PURE (-) 2-[1-(7-METHYL-2-(MORPHOLIN-4-YL)-4-OXO-4H-PYRIDO[1,2-A]PYRIMIDIN-9-YL)ETHYLAMINO]BENZOIC ACID, ITS USE IN MEDICAL THERAPY, AND A PHARMACEUTICAL COMPOSITION COMPRISING IT - 026 | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ITK, PI4KA, PIK3CA | PIK3CB 9/4885PIK3CA 3/4885PIK3CD 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.